Navigation Links
Supreme Court of Israel Rules in Favor of Sun Pharma

MUMBAI, India, Sept. 7 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Sun) (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that the Supreme Court of Israel has unanimously dismissed the appeal by Taro Pharmaceutical Industries Ltd. (Taro) (Pink Sheets: TAROF) of the previous ruling by the Tel-Aviv District Court holding that the Israeli special tender offer (STO) rules do not apply to the Tender Offer by Sun's subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), to purchase all outstanding Ordinary Shares of Taro for USD 7.75 net per Ordinary Share in cash.  The Court also lifted its temporary order that prohibited the closing of the Offer prior to its ruling.

In its 69-page decision, the three-judge bench of the Supreme Court of Israel said there were no legal or moral grounds upon which to require Sun to comply with the STO rules.  The Court declared that its ruling in favor of Sun was dictated by concerns of fairness, good faith and commercial stability and affirmed the District Court's finding that Taro and its directors had acted in bad faith.  The Court also awarded Sun expenses.

"Sun is gratified that the Supreme Court of Israel has upheld the decision of the Tel-Aviv District Court.  We are ready to finally move forward now to close the Offer and enforce our rights under the Option Agreement to purchase the Levitts' controlling shares," said Dilip Shanghvi, Chairman and Managing Director of Sun.

As previously announced, the Offer is scheduled to expire on the fifth business day following the date Sun announces a ruling on the appeal of the STO litigation.  Thus, the Offer is now set to expire at 12:00 midnight, New York City time, on Tuesday, September 14, 2010.  Also, as previously announced, Alkaloida will provide a subsequent offering period of not less than ten business days nor more than 20 business days following the expiration date.  As of 5:00 p.m., New York City time, on September 3, 2010, 28,882 Ordinary Shares had been tendered and not withdrawn from the Offer.

Sun also announced that at 11:59 p.m. on September 11, 2010, the clearance under the Hart-Scott-Rodino (HSR) Act waiting period previously obtained will expire.  Sun intends to re-file its HSR application to restart the HSR Act waiting period.  If, as of the expiration date, the number of Ordinary Shares tendered and not withdrawn from the Offer, together with the Ordinary Shares already beneficially owned by Sun, would result in Sun owning less than 50% of the voting power of Taro, there will be no applicable waiting period under the HSR Act and Alkaloida expects to close the Offer and promptly purchase such tendered Ordinary Shares.  If, as of such expiration date, the conditions to the Offer have not been satisfied or, to the extent permitted by applicable law, waived by Alkaloida, Alkaloida reserves the right to further extend the Offer.

The complete terms and conditions of the tender offer are set out in the Offer to Purchase, which is filed with the U.S. Securities and Exchange Commission.  Taro shareholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website ( or by directing a request to MacKenzie Partners, Inc., the Information Agent for the offer, at 105 Madison Avenue, New York, New York 10016, (212) 929-5500 (Call Collect) or Call Toll-Free (800) 322-2885, Email:

About Sun PharmaEstablished in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, specialty pharmaceutical company.  It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.  In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology.  The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at

ContactsUday Baldota

Mira DesaiTel

+91 22 6645 5645, Xtn 605


+91 22 6645 5645, Xtn 606Tel Direct

+91 22 66455605

Tel Direct

+91 22 66455606Mobile

+91 98670 10529


+91 98219 23797E mail

E mail Brunswick Group for Sun Pharma

MacKenzie PartnersErin Becker/Nicki Kahner

Robert Marese+1 212 333 3810

+1 212 929 5500Arad Communications for Sun Pharma

GreenhillIrit Radia

Ashish Contractor+972-54-6699311

+1 212 389 1537

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot
2. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
3. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
4. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
5. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
6. U.S. Appeals Court Reinstates Claim That Controversial Diet Drug Redux Should Never Have Been Offered to American People
7. German District Court Finds RENASYS™ GO NPWT System Non-infringing
8. U.S. Court of Appeals Rules on Validity of Lillys Gemzar Method-of-Use Patent
9. Federal Appeals Court Rules Pharmaceutical Sales Reps Entitled to Overtime Pay
10. Appellate Court Sides With Terminally-Ill Medical Marijuana Patient
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)...  Six months of adjunctive metformin therapy does not improve ... to new research from T1D Exchange and funded ... beneficial effect on measures of obesity, including weight and BMI. ... Journal of the American Medical Association , are from the ... on overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 Oct 2015, ... educate the personnel on spinal decompression therapy and offer his professional help. , ... The benefits come from creating negative intradiscal pressure which is conducive to retraction ...
(Date:12/1/2015)... ... 01, 2015 , ... World Patent Marketing , a vertically integrated ... allows for easier packing and organizing of items into one big, portable jar. , ... Cooper, CEO and Creative Director of World Patent Marketing and Desa Industries Inc ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article ... a discrimination claim against the U.S. Department of Health and Human Services, claiming that ... (ACA) plans are breaking the clause in the law prohibiting the denial of coverage ...
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... the United States, today announced that its iconic bottle has won top honors in ... drinks category. The Company also announced that it has been selected as a ...
Breaking Medicine News(10 mins):